Levels of both CD24 and EpCAM in EVs were shown to decrease among responding patients (n = 8, 1–6 directed surgical resection, 8 and 9 treated with chemotherapy), indicating that the proposed device could be used to monitor response to cancer therapies. This evidence concerns the gene EPCAM and cancer.